Introducing SERB Pharmaceuticals
SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.
We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
Who we are
SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).
Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks.
As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.
Improving patients’ quality of life and offering hope is what motivates and inspires us.
80+
Medicines
470+
Dedicated employees
Direct sales in
18
countries
Supplying
100+
countries
Latest news
Latest insight
08 April 2024
SERB publishes first Sustainability Report
Our first Sustainability Report is an important milestone in the company’s efforts to measure and improve our performance around environmental, social, and governance (ESG) issues.
Read more